Hematopoietic stem cell transplantation in peripheral T-cell lymphomas

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Peripheral T-cell lymphomas (PTCL) represent a rare group of aggressive non-Hodgkin's lymphomas (NHL) with a generally poor prognosis.
• Patients with PTCL often fare worse than those with B-cell NHL following conventional chemotherapy, with notable exceptions like anaplastic lymphoma-kinase (ALK)-positive anaplastic large cell lymphomas (ALCL).

Purpose of the Study:

• To evaluate the efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (SCT) in both upfront and relapsed settings for PTCL.
• To explore allogeneic SCT as a potential alternative treatment strategy for PTCL.
• To investigate the role of the graft-versus-lymphoma effect in improving outcomes for T-cell NHL patients.

Main Methods:

• Review of available data on autologous SCT in the upfront and relapsed settings for PTCL.
• Analysis of preliminary results concerning allogeneic SCT for PTCL.
• Comparison of treatment outcomes between different PTCL subtypes and B-cell NHL.

Main Results:

• Autologous SCT demonstrated an advantage when utilized as a first-line treatment for PTCL.
• Autografting at relapse yielded satisfactory results primarily for ALK-positive ALCLs, with less favorable outcomes for other PTCL subtypes.
• Allogeneic SCT is emerging as a viable alternative strategy for managing these lymphomas.

Conclusions:

• High-dose chemotherapy with autologous SCT is more effective in the upfront setting than at relapse for most PTCL subtypes.
• Allogeneic SCT presents a promising alternative, though further research is needed to confirm its benefit.
• The potential of the graft-versus-lymphoma effect to overcome the dismal prognosis of T-cell NHL requires further investigation.